Top

Published in:

13-06-2022 | IgA Vasculitis | Case Based Review

Vasculitis flare after COVID-19: report of two cases in patients with preexistent controlled IgA vasculitis and review of the literature

Authors: Cristina Valero, Juan Pablo Baldivieso-Achá, Miren Uriarte, Esther F. Vicente-Rabaneda, Santos Castañeda, Rosario García-Vicuña

Published in: Rheumatology International | Issue 9/2022

Abstract

COVID-19 has been related to several autoimmune diseases, triggering the appearance of autoantibodies and endothelial dysfunction. Current evidence has drawn attention to vasculitis-like phenomena and leukocytoclastic vasculitis in some COVID-19 patients. Moreover, it has been hypothesized that COVID-19 could induce flares of preexisting autoimmune disorders. Here, we present two patients with previously controlled IgA vasculitis who developed a renal and cutaneous flare of vasculitis after mild COVID-19, one of them with new-onset ANCA vasculitis. These patients were treated with glucocorticoids and immunosuppressants achieving successful response. We also provide a focused literature review and conclude that COVID-19 may be associated with triggering of vasculitis and could induce flares of previous autoimmune diseases.

Skendros P, Mitsios A, Chrysanthopoulou A et al (2020) Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J Clin Invest 130(11):6151–6157. https://doi.org/10.1172/JCI141374CrossRefPubMedPubMedCentral

Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y (2021) The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev 20(4):102792. https://doi.org/10.1016/j.autrev.2021.102792CrossRefPubMedPubMedCentral

Ehrenfeld M, Tincani A, Andreoli L et al (2020) Covid-19 and autoimmunity. Autoimmun Rev 19(8):102597. https://doi.org/10.1016/j.autrev.2020.102597CrossRefPubMedPubMedCentral

Veras FP, Pontelli MC, Silva CM et al (2020) SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology. J Exp Med 217(12):e20201129. https://doi.org/10.1084/jem.20201129CrossRefPubMedPubMedCentral

Zhou Y, Han T, Chen J et al (2020) Clinical and Autoimmune characteristics of severe and critical cases of COVID-19. Clin Transl Sci 13(6):1077–1086. https://doi.org/10.1111/cts.12805CrossRefPubMedPubMedCentral

Vlachoyiannopoulos PG, Magira E, Alexopoulos H et al (2020) Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. Ann Rheum Dis 79:1661–1663. https://doi.org/10.1136/annrheumdis-2020-218009CrossRefPubMed

Gkrouzman E, Barbhaiya M, Erkan D, Lockshin MD (2021) Reality check on antiphospholipid antibodies in COVID-19-associated coagulopathy. Arthritis Rheumatol 73(1):173–174. https://doi.org/10.1002/art.41472CrossRefPubMed

Uppal NN, Kello N, Shah HH et al (2020) De novo ANCA-associated vasculitis with glomerulonephritis in COVID-19. Kidney Int Rep 5(11):2079–2083. https://doi.org/10.1016/j.ekir.2020.08.012CrossRefPubMedPubMedCentral

Moeinzadeh F, Dezfouli M, Naimi A, Shahidi S, Moradi H (2020) Newly diagnosed glomerulonephritis during COVID-19 infection undergoing immunosuppression therapy, a case report. Iran J Kidney Dis 14(3):239–242 (PMID: 32361703)PubMed

10.

Hussein A, Al Khalil K, Bawazir YM (2020) Anti-neutrophilic cytoplasmic antibody (ANCA) vasculitis presented as pulmonary hemorrhage in a positive COVID-19 patient: a case report. Cureus 12(8):e9643. https://doi.org/10.7759/cureus.9643CrossRefPubMedPubMedCentral

11.

Selvaraj V, Moustafa A, Dapaah-Afriyie K, Birkenbach MP (2021) COVID-19-induced granulomatosis with polyangiitis. BMJ Case Rep 14(3):e242142. https://doi.org/10.1136/bcr-2021-242142CrossRefPubMedPubMedCentral

12.

Jalalzadeh M, Valencia-Manrique JC, Boma N, Chaudhari A, Chaudhari S (2021) Antineutrophil cytoplasmic antibody-associated glomerulonephritis in a case of scleroderma after recent diagnosis with COVID-19. Cureus 13(1):e12485. https://doi.org/10.7759/cureus.12485CrossRefPubMedPubMedCentral

13.

Singh S, Vaghaiwalla Z, Thway M, Kaeley GS (2021) Does withdrawal of immunosuppression in rheumatoid arthritis after SARS-CoV-2 infection increase the risk of vasculitis? BMJ Case Rep 14(4):e241125. https://doi.org/10.1136/bcr-2020-241125CrossRefPubMedPubMedCentral

14.

Powell WT, Campbell JA, Ross F, Peña Jiménez P, Rudzinski ER, Dickerson JA (2021) Acute ANCA vasculitis and asymptomatic COVID-19. Pediatrics 147(4):e2020033092. https://doi.org/10.1542/peds.2020-033092CrossRefPubMed

15.

du Merveilleux Vignaux C, Ahmad K, Tantot J, Rouach B, Traclet J, Cottin V (2021) Evolution from hypereosinophilic bronchiolitis to eosinophilic granulomatosis with polyangiitis following COVID-19: a case report. Clin Exp Rheumatol 39(128(1)):11–12 (PMID: 33506754)

16.

Izci Duran T, Turkmen E, Dilek M, Sayarlioglu H, Arik N (2021) ANCA-associated vasculitis after COVID-19. Rheumatol Int 41(8):1523–1529. https://doi.org/10.1007/s00296-021-04914-3CrossRefPubMedPubMedCentral

17.

Reiff DD, Meyer CG, Marlin B, Mannion ML (2021) New onset ANCA-associated vasculitis in an adolescent during an acute COVID-19 infection: a case report. BMC Pediatr 21(1):333. https://doi.org/10.1186/s12887-021-02812-yCrossRefPubMedPubMedCentral

18.

Maritati F, Moretti MI, Nastasi V et al (2021) ANCA-associated glomerulonephritis and anti-phospholipid syndrome in a patient wITH SARS-CoV-2 infection: just a coincidence? Case Rep Nephrol Dial 11(2):214–220. https://doi.org/10.1159/000517513CrossRefPubMedPubMedCentral

19.

Lind E, Jameson A, Kurban E (2021) Fulminant granulomatosis with polyangiitis presenting with diffuse alveolar haemorrhage following COVID-19. BMJ Case Rep 14(6):e242628. https://doi.org/10.1136/bcr-2021-242628 (PMID:34155024;PMCID:PMC8217953)CrossRefPubMedPubMedCentral

20.

Patel R, Amrutiya V, Baghal M, Shah M, Lo A (2021) Life-threatening diffuse alveolar hemorrhage as an initial presentation of microscopic polyangiitis: COVID-19 as a likely culprit. Cureus 13(4):e14403. https://doi.org/10.7759/cureus.14403CrossRefPubMedPubMedCentral

21.

Allena N, Patel J, Nader G, Patel M, Medvedovsky B (2021) A rare case of SARS-CoV-2-induced microscopic polyangiitis. Cureus 13(5):e15259. https://doi.org/10.7759/cureus.15259CrossRefPubMedPubMedCentral

22.

Fireizen Y, Shahriary C, Imperial ME, Randhawa I, Nianiaris N, Ovunc B (2021) Pediatric P-ANCA vasculitis following COVID-19. Pediatr Pulmonol 56(10):3422–3424. https://doi.org/10.1002/ppul.25612CrossRefPubMedPubMedCentral

23.

Mashinchi B, Aryannejad A, Namazi M et al (2021) A Case of C-ANCA positive systematic lupus erythematous and anca-associated vasculitis overlap syndrome superimposed by COVID-19: a fatal trio. Mod Rheumatol Case Rep. https://doi.org/10.1093/mrcr/rxab007CrossRefPubMedPubMedCentral

24.

Li NL, Papini AB, Shao T, Girard L (2021) Immunoglobulin-a vasculitis with renal involvement in a patient with COVID-19: a case report and review of acute kidney injury related to SARS-CoV-2. Can J Kidney Health Dis 8:2054358121991684. https://doi.org/10.1177/2054358121991684CrossRefPubMedPubMedCentral

25.

Suso AS, Mon C, Alonso IO et al (2020) IgA vasculitis with nephritis (Henoch-Schonlein purpura) in a COVID-19 patient. Kidney Int Rep 5:2074–2078. https://doi.org/10.1016/j.ekir.2020.08.016CrossRefPubMedPubMedCentral

26.

Hoskins B, Keeven N, Dang M, Keller E, Nagpal R (2021) A child with COVID-19 and immunoglobulin a vasculitis. Pediatr Ann 50(1):e44–e48. https://doi.org/10.3928/19382359-20201211-01CrossRefPubMed

27.

Allez M, Denis B, Bouaziz JD et al (2020) COVID-19-related IgA vasculitis. Arthritis Rheumatol 72(11):1952–1953. https://doi.org/10.1002/art.41428CrossRefPubMedPubMedCentral

28.

Barbetta L, Filocamo G, Passoni E, Boggio F, Folli C, Monzani V (2021) Henoch-Schönlein purpura with renal and gastrointestinal involvement in course of COVID-19: a case report. Clin Exp Rheumatol 39(129(2)):191–192 (PMID: 33769259)CrossRef

29.

AlGhoozi DA, AlKhayyat HM (2021) A child with Henoch-Schonlein purpura secondary to a COVID-19 infection. BMJ Case Rep 14(1):e239910. https://doi.org/10.1136/bcr-2020-239910CrossRefPubMed

30.

Sandhu S, Chand S, Bhatnagar A et al (2021) Possible association between IgA vasculitis and COVID-19. Dermatol Ther 34(1):e14551. https://doi.org/10.1111/dth.14551CrossRefPubMed

31.

Jacobi M, Lancrei HM, Brosh-Nissimov T, Yeshayahu Y (2021) Purpurona: a novel report of COVID-19-related Henoch-Schonlein Purpura in a child. Pediatr Infect Dis J 40(2):e93–e94. https://doi.org/10.1097/INF.0000000000003001CrossRefPubMed

32.

Huang Y, Li XJ, Li YQ et al (2020) Clinical and pathological findings of SARS-CoV-2 infection and concurrent IgA nephropathy: a case report. BMC Nephrol 21:504. https://doi.org/10.1186/s12882-020-02163-3CrossRefPubMedPubMedCentral

33.

El Hasbani G, Taher AT, Jawad ASM, Uthman I (2021) Henoch-Schönlein purpura: another COVID-19 complication. Pediatr Dermatol. https://doi.org/10.1111/pde.14699CrossRefPubMed

34.

Nakandakari Gomez MD, Marin Macedo H, SeminarioVilca R (2021) IgA vasculitis (Henoch Schönlein Purpura) in a pediatric patient with COVID-19 and strongyloidiasis. Rev Fac Med Humana 21(1):184–190. https://doi.org/10.25176/RFMH.v21i1.3265CrossRef

35.

Falou S, Kahil G, AbouMerhi B, Dana R, Chokr I (2021) Henoch Schonlein Purpura as possible sole manifestation of Covid-19 in children. Acta Sci Paediatr 4(4):27–29CrossRef

36.

Oñate I, Ortiz M, Suso A et al (2021) Ig A vasculitis with nephritis (henoch-schönlein purpura) after covid-19: a case series and review of the literature. Nefrologia. https://doi.org/10.1016/j.nefro.2021.07.009CrossRefPubMedPubMedCentral

37.

Novelli L, Motta F, De Santis M, Ansari AA, Gershwin ME, Selmi C (2021) The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19—a systematic review of the literature. J Autoimmun 117:102592. https://doi.org/10.1016/j.jaut.2020.102592CrossRefPubMed

38.

Calabrese L, Winthrop KL (2021) Rheumatology and COVID-19 at 1 year: facing the unknowns. Ann Rheum Dis 80(6):679–681. https://doi.org/10.1136/annrheumdis-2021-219957CrossRefPubMed

39.

Teng GG, Chatham WW (2015) Vasculitis related to viral and other microbial agents. Best Pract Res Clin Rheumatol 29(2):226–243. https://doi.org/10.1016/j.berh.2015.05.007CrossRefPubMed

40.

Haq SA, Pagnoux C (2019) Infection-associated vasculitides. Int J Rheum Dis 22(1):109–115. https://doi.org/10.1111/1756-185X.13287CrossRefPubMed

41.

Konstantinov KN, Ulff-Møller CJ, Tzamaloukas AH (2015) Infections and antineutrophil cytoplasmic antibodies: triggering mechanisms. Autoimmun Rev 14(3):201–203. https://doi.org/10.1016/j.autrev.2014.10.020.15a22CrossRefPubMed

42.

Becker RC (2020) COVID-19-associated vasculitis and vasculopathy. J Thromb Thrombolysis 50(3):499–511. https://doi.org/10.1007/s11239-020-02230-4CrossRefPubMedPubMedCentral

43.

Gisondi P, PIaserico S, Bordin C, Alaibac M, Girolomoni G, Naldi L (2020) Cutaneous manifestations of SARS-CoV-2 infection: a clinical update. J Eur Acad Dermatol Venereol 34(11):2499–2504. https://doi.org/10.1111/jdv.16774CrossRefPubMedPubMedCentral

44.

Caputo V, Schroeder J, Rongioletti F (2020) A generalized purpuric eruption with histopathologic features of leucocytoclastic vasculitis in a patient severely ill with COVID-19. J Eur Acad Dermatol Venereol 34(10):579–581. https://doi.org/10.1111/jdv.16737CrossRef

45.

Camprodon Gómez M, González-Cruz C, Ferrer B, Barberá MJ (2020) Leucocytoclastic vasculitis in a patient with COVID-19 with positive SARS-CoV-2 PCR in skin biopsy. BMJ Case Rep 13(10):e238039. https://doi.org/10.1136/bcr-2020-238039CrossRefPubMedPubMedCentral

46.

Gracia-Ramos AE, Saavedra-Salinas MA (2021) Can the SARS-CoV-2 infection trigger systemic lupus erythematosus? A case-based review. Rheumatol Int 41:799–809. https://doi.org/10.1007/s00296-021-04794-7CrossRefPubMedPubMedCentral

47.

Fike A, Hartman J, Redmond C et al (2021) Risk factors for COVID-19 and rheumatic disease flare in a US cohort of Latino patients. Arthritis Rheumatol. https://doi.org/10.1002/art.41656CrossRefPubMedPubMedCentral

Title: Vasculitis flare after COVID-19: report of two cases in patients with preexistent controlled IgA vasculitis and review of the literature
Authors: Cristina Valero
Juan Pablo Baldivieso-Achá
Miren Uriarte
Esther F. Vicente-Rabaneda
Santos Castañeda
Rosario García-Vicuña
Publication date: 13-06-2022
Publisher: Springer Berlin Heidelberg
Keywords: IgA Vasculitis
ANCA-Associated Vasculitis
Vasculitis
IgA Vasculitis
ANCA-Associated Vasculitis
Vasculitis
Leukocytoclastic Vasculitis
Leukocytoclastic Vasculitis
Glucocorticoid
Rituximab
SARS-CoV-2
Pneumonia
COVID-19
Glomerulonephritis
Rituximab
Published in: Rheumatology International / Issue 9/2022
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-022-05153-w

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2022

Behçet's disease with intestinal involvement: case-based review

Monitoring of rheumatoid arthritis: a patient survey on disease insight and possible added value of an innovative inflammation monitoring device

Assessment of autonomic dysfunction with the COMPASS-31 and its relationship with disease activity and cardiovascular risks in patients with psoriatic arthritis

Prevalence of joint-specific osteoarthritis and joint pain in British Columbia, Canada

Anti-MDA5 dermatomyositis after COVID-19 vaccination: a case-based review

The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials